You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《港股》恆指半日跌101點 機械人概念股倒跌 個別藥股逆漲
投資者關注債息上升,美股道指跌0.6%。港股早市先升後跌,恆指高開164點,初段升293點見25,789點後回落,曾跌144點一度低見25,351點,半日跌101點或0.4%,報25,395點;國指跌47點或0.5%,報9,060點;恆生科技指數跌31點或0.5%,報5,697點。大市半日成交總額1,520.18億元。 科技股方面,阿里(09988.HK)及騰訊(00700.HK)跌0.4%及0.2%,中芯(00981.HK)、小米(01810.HK)、美團(03690.HK)、網易(09999.HK)及嗶哩嗶哩(09626.HK)跌1.1%至1.6%,京東(09618.HK)及百度(09888.HK)升1.3%及2.7%,快手(01024.HK)升0.3%。醫療平台平安好醫生(01833.HK)及阿里健康(00241.HK)升9.2%及4.1%,手機相關股比亞迪電子(00285.HK)回吐3.9%。 宇樹科技預告今年內提交IPO申請,在港上市機器人概念股優必選(09880.HK)及越疆(02432.HK)倒跌2.1%及2%。首程控股(00697.HK)升4.6%,該公司旗下基金投資宇樹科技。 蔚來(09866.HK)季度經調整淨虧損按年收窄9%,公司第四季目標每月交付量達5萬輛,股價升0.9%。理想(02015.HK)升1.7%,比亞迪(01211.HK)及小鵬(09868.HK)跌1.5%及1.9%。汽車代理中升(00881.HK)獲瑞銀上調評級至「買入」,股價升4.6%。藥明合聯(02268.HK)折讓4%配股淨籌13億元,股價升5.5%。同系藥明生物(02269.HK)升1.6%。其他醫藥股方面,恆瑞醫藥(01276.HK)、諾誠健華(09969.HK)及石藥(01093.HK)升5.7%、4.7%及3.9%。 金融股方面,匯控(00005.HK)升0.2%,港交所(00388.HK)及友邦(01299.HK)跌0.8%及0.2%,富衛(01828.HK)升2.5%。中國平安(02318.HK)增持國壽(02628.HK)4,409.5萬股,中國平安及國壽隨大市跌0.4%及0.6%。券商股中金(03908.HK)跌3.1%。 期金升穿3,600美元水平,紫金(02899.HK)及招金(01818.HK)升1.4%及1.6%,山東黃金(01787.HK)倒跌0.7%。金屬股江銅(00358.HK)及中鋁(02600.HK)升4%及2.8%。金飾零售股六福(00590.HK)、周大福(01929.HK)及周生生(00116.HK)升2.6%至3.2%,老鋪黃金(06181.HK)升1.5%。 長飛光纖光纜(06869.HK)半日炒高9.2%,成交逾21億元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account